Produktname:4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]aniline
IUPAC Name:4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]aniline
- CAS：2448173-20-2
- Molekulare Formel：C16H17N5O
- Reinheit：95%+
- Katalognummer：CM1045041
- Molekulargewicht：295.35
| Packungseinheit |
Verfügbarer Vorrat |
Preis($) |
Menge |
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:2448173-20-2
- Molekulare Formel:C16H17N5O
- Schmelzpunkt:-
- SMILES-Code:NC1=CC=C(C=C1)C1=CC2=C(N=CN=C2N1)N1CCOCC1
- Dichte:
- Katalognummer:CM1045041
- Molekulargewicht:295.35
- Siedepunkt:
- Mdl-Nr.:
- Lagerung:
Category Infos
- Pyrrolopyrimidines
- Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.
Column Infos
- BMF-219
- Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.
Suche 
+86 21 5895 0110 
